Exhibit 99.1
NEWS RELEASE- DRAFT
FOR IMMEDIATE RELEASE | | CONTACT: | | Watson Pharmaceuticals, Inc. |
| | | | Patty Eisenhaur |
| | | | (951) 493-5611 |
WATSON PHARMACEUTICALS REPORTS
THIRD QUARTER 2006 RESULTS
CORONA, CA — November 7, 2006 — Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2006.
Net revenue for the third quarter increased seven percent to $440.5 million, compared to $410.3 million for the third quarter ended September 30, 2005. Third quarter total net revenue growth was driven by higher product sales in the Company’s Generic division as a result of new products launched since the third quarter of 2005, and was partially offset by lower Brand product sales.
The Company recorded net income for the third quarter of $34.4 million, or $0.31 per diluted share, compared to net income of $39.1 million, or $0.35 per diluted share, for the same period of 2005. Net income for the third quarter included $4.4 million ($2.8 million, net of tax or $0.02 per diluted share) of facility rationalization costs.
Cash flow from operations was $141.5 million for the third quarter and $337.8 million for the first nine months of 2006. Cash and marketable securities were $906.8 million as of September 30, 2006.
“Our business continues to generate strong operating cash flow, allowing us to close the Andrx acquisition with lower than expected borrowings and a strong balance sheet going into 2007,” began Allen Chao, Ph.D., Watson’s Chairman and Chief Executive Officer.
“As we announced on November 6th, we are very pleased with the close of the Andrx acquisition,” continued Dr. Chao. “Andrx not only strengthens our competitive position in sustained-release technology, but broadens our product portfolio and pipeline. We now have 66 pending abbreviated new drug applications on file with FDA. The addition of Andrx is just one of several strategic initiatives we have undertaken to enhance long term revenue growth, reduce costs and achieve operating efficiencies,” Dr. Chao concluded.
For the nine months ended September 30, 2006, total net revenue increased 11 percent to $1,358.1 million, as compared to $1,227.4 million for the first nine months of 2005. Net income for the first nine months of 2006 was $44.0 million, or $0.43 per basic and diluted share, as compared to net income of $118.1 million, or $1.02 per diluted share, for the same period of 2005.
Third Quarter 2006 Results
Net Revenues
| | Three Months Ended September 30, | |
($ in millions): | | 2006 | | 2005 | | Change | |
Generic products | | | | | | | |
Generics | | $ | 263.7 | | $ | 234.1 | | 13 | % |
Generic oral contraceptives | | 83.9 | | 81.1 | | 3 | % |
Total generic product sales | | 347.6 | | 315.2 | | 10 | % |
% of product net sales | | 80 | % | 77 | % | | |
Brand products | | | | | | | |
Specialty Products | | 43.9 | | 46.4 | | (5 | )% |
Nephrology | | 41.7 | | 45.2 | | (8 | )% |
Total brand product sales | | 85.6 | | 91.6 | | (7 | )% |
% of product net sales | | 20 | % | 23 | % | | |
Total product net sales | | 433.2 | | 406.8 | | 6 | % |
Other | | 7.3 | | 3.5 | | 109 | % |
Total net revenues | | $ | 440.5 | | $ | 410.3 | | 7 | % |
| | Nine Months Ended September 30, | |
| | 2006 | | 2005 | | Change | |
Generic products | | | | | | | |
Generics | | $ | 850.0 | | $ | 680.1 | | 25 | % |
Generic oral contraceptives | | 238.5 | | 240.8 | | (1 | )% |
Total generic product sales | | 1,088.5 | | 920.9 | | 18 | % |
% of product net sales | | 81 | % | 76 | % | | |
Brand products | | | | | | | |
Specialty Products | | 127.4 | | 164.5 | | (23 | )% |
Nephrology | | 129.4 | | 132.3 | | (2 | )% |
Total brand products | | 256.8 | | 296.8 | | (13 | )% |
% of product net sales | | 19 | % | 24 | % | | |
Total product net sales | | 1,345.3 | | 1,217.7 | | 10 | % |
Other | | 12.8 | | 9.7 | | 31 | % |
Total net revenues | | $ | 1,358.1 | | $ | 1,227.4 | | 11 | % |
Generic product sales for the third quarter increased $32.4 million or 10 percent to $347.6 million, compared to $315.2 million in the prior year period, due to the addition of pravastatin sodium tablets and oxycodone HCl controlled-release tablets C-II. On a sequential quarter basis, generic product sales decreased $71.8 million or 17 percent from the second quarter 2006, largely due to lower sales of pravastatin sodium, in anticipation of additional competition in late October.
Brand product sales for the third quarter decreased $6.0 million or 7 percent to $85.6 million, compared to $91.6 million in the third quarter of 2005, due to a decline in sales of Ferrlecit® within Watson’s Nephrology franchise and lower pricing on Trelstar™.
Gross Margin
| | Three Months Ended | |
| | September 30, | |
| | 2006 | | 2005 | |
Overall consolidated gross margin | | 41.5 | % | 48.6 | % |
| | | | | |
Generic product sales | | 32.4 | % | 40.6 | % |
Brand product sales | | 73.2 | % | 74.4 | % |
Gross margin on product net sales | | 40.5 | % | 48.2 | % |
Gross profit was $182.6 million in the third quarter of 2006, compared to $199.5 million for the third quarter of 2005 and $179.5 million in the second quarter 2006. The decrease in gross profit compared to the prior year period was due primarily to lower generic product pricing from the year ago period.
Overall gross margin was 41.5 percent in the third quarter of 2006 compared to 48.6 percent in the third quarter of 2005 and 35.2 percent in the second quarter 2006. The addition of pravastatin sodium tablets and oxycodone HCl controlled-release tablets, both distributed generic products with lower gross margins contributed to the year over year decline. The improvement in gross margin compared to the second quarter 2006 was due to a favorable product mix.
Operating expenses decreased $2.8 million or two percent to $133.3 million in the third quarter.
Generic Research and Development
With the recent addition of Andrx’s generic pipeline, Watson currently has 66 Abbreviated New Drug Applications (ANDAs) on file with the U.S. Food and Drug Administration (FDA).
Brand Research and Development
In Watson’s brand product pipeline, the Company has completed the efficacy portion of its Phase III program for silodosin, a product under development for benign prostatic hyperplasia. A one-year open label study is underway and is expected to be complete in the second half of 2007. Additionally, Phase III studies on Watson’s gel formulation of oxybutynin for overactive bladder remain ongoing and the Company remains on target to complete the studies in mid 2007.
2006 Financial Outlook
Watson’s forecasts are based on the Company’s actual results for the first nine months of 2006, management’s current belief about prescription and pricing trends, customer inventory levels and the anticipated timing of future product launches. Watson expects to realize approximately two months of Andrx’s operating results in its full year 2006 results. Due to the timing of the close of the Andrx acquisition on
November 3, 2006, and numerous adjustments anticipated following the close of the transaction, the Company is not prepared to provide a forecast for its full year 2006 results on a combined basis. Excluding revenue anticipated from certain new product launches and the impact of the Andrx acquisition on the Company’s financial results for the fourth quarter, Watson expects its fourth quarter operating results to be similar to third quarter levels.
Webcast and Conference Call Details
Watson will host a conference call and webcast today at 5:00 p.m. Eastern Standard Time to discuss 2006 third quarter results, projections for the remainder of 2006 and recent corporate developments. The dial-in number to access the call is (877) 251-7980, or from international locations, (706) 643-1573. A taped replay of the call will be available by calling (800) 642-1687 with access pass code 8563225. The replay may be accessed from international locations by dialing (706) 645-9291 and using the same pass code. This replay will remain in effect until midnight Eastern Standard Time, Tuesday, November 14, 2006. To access the live webcast, go to Watson’s Investor Relations Web site at http://ir.watsonpharm.com.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc., headquartered in Corona, California, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.
For press release and other company information, visit Watson Pharmaceuticals’ Web site at http://www.watsonpharm.com.
Forward-Looking Statement
Statements contained in this press release that refer to Watson’s estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Watson’s current perspective of existing trends and information as of the date of this release. For instance, any statements in this press release concerning prospects related to Watson’s strategic initiatives, product introductions and anticipated financial performance are forward-looking statements. It is important to note that Watson’s goals and expectations are not predictions of actual performance. Watson’s performance, at times, will differ from its goals and expectations. Actual results may differ materially from Watson’s current expectations depending upon a number of factors affecting Watson’s business. These factors include, among others, the inherent uncertainty associated with financial projections; the impact of competitive products and pricing; successful integration of strategic transactions, including the Company’s March 16, 2006 acquisition of Sekhsaria Chemicals, Ltd. and its November 3, 2006 acquisition of Andrx Corporation; the ability to timely and cost effectively integrate Watson and Andrx’s operations; the ability to recognize the anticipated synergies and benefits of strategic transactions, including the Andrx acquisition; the ability to timely resolve with FDA the pending Official Action Indicated status of the Davie, Florida manufacturing facility; variability of revenue mix between the Company’s Brand and Generic business units; periodic dependence on a small number of products for a material source of net revenue or income; variability of trade buying patterns; changes in generally accepted accounting principles; risks that
the carrying values of assets may be negatively impacted by future events and circumstances; timely and successful consummation and implementation of strategic initiatives; the timing and success of product launches; the difficulty of predicting the timing or outcome of product development efforts and FDA or other regulatory agency approvals or actions; the uncertainty associated with the identification and successful consummation of external business development transactions; market acceptance of and continued demand for Watson’s products; costs and efforts to defend or enforce intellectual property rights; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson’s and its third party manufacturers’ facilities, products and/or business; uncertainties related to the timing and outcome of litigation and other claims; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson’s periodic public filings with the Securities and Exchange Commission, including but not limited to Watson’s Annual Report on Form 10-K for the year ended December 31, 2005 and Watson’s Quarterly Report on Form 10-Q for the period ended June 30, 2006. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.
The following table presents Watson’s results of operations for the three and nine months ended September 30, 2006 and 2005:
Table 1
Watson Pharmaceuticals, Inc.
Condensed Consolidated Statements of Income
(Unaudited; in thousands, except per share amounts)
| | Three Months Ended | | Nine Months Ended | |
| | September 30, | | September 30, | |
| | 2006 | | 2005 | | 2006 | | 2005 | |
| | | | Restated | | | | Restated | |
Net revenues | | $ | 440,493 | | $ | 410,296 | | $ | 1,358,082 | | $ | 1,227,390 | |
Cost of sales (excludes amortization presented below) | | 257,896 | | 210,809 | | 823,510 | | 628,972 | |
Gross profit | | 182,597 | | 199,487 | | 534,572 | | 598,418 | |
| | | | | | | | | |
Operating expenses: | | | | | | | | | |
Research and development | | 29,447 | | 29,840 | | 90,409 | | 90,164 | |
Selling, general and administrative | | 64,467 | | 65,175 | | 201,991 | | 196,951 | |
Amortization | | 39,392 | | 41,100 | | 121,593 | | 122,839 | |
Loss on impairment | | — | | — | | 66,981 | | — | |
Total operating expenses | | 133,306 | | 136,115 | | 480,974 | | 409,954 | |
Operating income | | 49,291 | | 63,372 | | 53,598 | | 188,464 | |
| | | | | | | | | |
Other income (expense): | | | | | | | | | |
Earnings (losses) on equity method investments | | 184 | | (810 | ) | 1,638 | | (1,685 | ) |
Gain on sale of securities | | — | | — | | 3,695 | | — | |
Loss on early extinguishment of debt | | — | | — | | (525 | ) | — | |
Interest income | | 9,601 | | 4,928 | | 22,766 | | 13,580 | |
Interest expense | | (3,814 | ) | (4,690 | ) | (10,437 | ) | (11,604 | ) |
Other expense | | (428 | ) | (450 | ) | (420 | ) | (489 | ) |
Total other income, net | | 5,543 | | (1,022 | ) | 16,717 | | (198 | ) |
| | | | | | | | | |
Income before income tax provision | | 54,834 | | 62,350 | | 70,315 | | 188,266 | |
Provision for income taxes | | 20,453 | | 23,264 | | 26,320 | | 70,118 | |
Net income | | $ | 34,381 | | $ | 39,086 | | $ | 43,995 | | $ | 118,148 | |
| | | | | | | | | |
Diluted earnings per share | | $ | 0.31 | | $ | 0.35 | | $ | 0.43 | | $ | 1.02 | |
| | | | | | | | | |
Diluted weighted average shares outstanding | | 116,353 | | 118,158 | | 116,356 | | 121,156 | |
The following table presents Watson’s Condensed Consolidated Balance Sheets as of September 30, 2006 and December 31, 2005:
Table 2
Watson Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(Unaudited; in thousands)
| | September 30, | | December 31, | |
| | 2006 | | 2005 | |
Assets | | | | | |
| | | | | |
Cash and cash equivalents | | $ | 735,222 | | $ | 467,451 | |
Marketable securities | | 171,545 | | 162,475 | |
Accounts receivable, net | | 264,264 | | 333,832 | |
Inventories | | 318,166 | | 278,062 | |
Other current assets | | 133,260 | | 118,610 | |
Property and equipment, net | | 444,043 | | 436,149 | |
Investments and other assets | | 91,198 | | 76,051 | |
Product rights, net | | 561,409 | | 751,808 | |
Goodwill | | 479,926 | | 455,595 | |
Total assets | | $ | 3,199,033 | | $ | 3,080,033 | |
| | | | | |
Liabilities & Stockholders’ Equity | | | | | |
| | | | | |
Current liabilities | | $ | 349,778 | | $ | 245,670 | |
Long-term debt | | 574,078 | | 587,935 | |
Deferred income taxes and other liabilities | | 104,760 | | 142,187 | |
Stockholders’ equity | | 2,170,417 | | 2,104,241 | |
Total liabilities & stockholders’ equity | | $ | 3,199,033 | | $ | 3,080,033 | |
The following table presents Watson’s Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2006 and 2005:
Table 3
Watson Pharmaceuticals, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited; in thousands)
| | Nine Months Ended
September 30, | |
| | 2006 | | 2005 | |
| | | | Restated | |
Cash Flows from Operating Activities: | | | | | |
Net income | | $ | 43,995 | | $ | 118,148 | |
Reconciliation to net cash provided by operating activities: | | | | | |
Depreciation and amortization | | 158,620 | | 153,696 | |
Loss on impairment | | 66,981 | | — | |
Deferred income tax provision (benefit) | | (54,111 | ) | (10,746 | ) |
Provision for inventory reserve | | 18,126 | | 36,607 | |
Restricted stock and stock option compensation | | 9,731 | | 1,175 | |
Other adjustments to reconcile net income to net cash provided | | (7,377 | ) | 4,026 | |
Changes in assets and liabilities: | | | | | |
Accounts receivable, net | | 69,931 | | (39,189 | ) |
Inventories | | (53,712 | ) | 12,947 | |
Accounts payable and accrued expense | | 40,445 | | 1,706 | |
Income taxes payable | | 48,183 | | (11,444 | ) |
Other changes to assets and liabilities | | (3,045 | ) | 12,555 | |
Total adjustments | | 293,772 | | 161,333 | |
Net cash provided by operating activities | | 337,767 | | 279,481 | |
Cash Flows from Investing Activities: | | | | | |
Additions to property, equipment and product right intangibles | | (25,908 | ) | (48,834 | ) |
Proceeds from sales of marketable securities | | 3,693 | | 220,083 | |
Acquisition of Sekhsaria | | (29,574 | ) | — | |
Other | | (7,209 | ) | (2,518 | ) |
Net cash (used in) provided by investing activities | | (58,998 | ) | 168,731 | |
| | | | | |
Cash Flows from Financing Activities: | | | | | |
Redemption of senior unsecured notes | | (14,585 | ) | — | |
Repurchase of common stock | | — | | (300,000 | ) |
Proceeds from stock plans and other | | 7,928 | | 25,366 | |
Other | | (4,341 | ) | (7 | ) |
Net cash used in financing activities | | (10,998 | ) | (274,641 | ) |
Net increase in cash and cash equivalents | | 267,771 | | 173,571 | |
Cash and cash equivalents at beginning of period | | 467,451 | | 298,653 | |
Cash and cash equivalents at end of period | | $ | 735,222 | | $ | 472,224 | |
